Your Impact on Research

Home Research Your Impact on Research

The Pancreatic Cancer Action Network has invested tens of millions of dollars in research grants to advance science and medicine and improve outcomes for patients.

  • Since 2003, we have awarded 167 grants to 166 scientists at 62 institutions and our cumulative research investment is projected to be more than $56 million to date, including our competitive Research Grants Program and leading-edge scientific and clinical initiatives.
  • Between 2003- 2015, for every dollar we awarded, grantees were able to leverage an additional $11.01 in subsequent pancreatic cancer research funding to support their research.
  • During that same time period, the 123 researchers we awarded with grants authored 1,983 articles in peer-reviewed biomedical journals.
  • The 1,983 articles have already been cited more than 11,000 times in other papers published in biomedical journals, which means other researchers are reading, learning from and building upon our grantees’ work.


Your support advances scientific progress for patients facing pancreatic cancer. Here are a few examples of our impact:

  • Unlocking the Biology
  • The pancreatic cancer mouse model used today

  • David Tuveson, MD, PhD and
    Sunil Hingorani, MD, PhD
    2003 & 2005 Career Development Awards
    Dr. Laurence A. Mack and Roselle Mack

  • Our grant supported the development of the first genetically-engineered mouse model that accurately mimics human disease progression. The mice are genetically programmed to develop pancreatic cancer that starts with precancerous abnormalities and progresses to invasive and then metastatic disease. Additionally, the mouse model’s pancreatic tumors are surrounded by a dense shell that mimics the complex and challenging tumor microenvironment (stroma) in human disease. To this day, this continues to be the mouse model used in labs around the world to advance better treatments for patients facing pancreatic cancer.

    Read More

  • Risk Factors
  • Oral bacteria increasing risk

  • Jiyoung Ahn, PhD
    2012 Career Development Award
    The Daniel and Janet Mordecai Foundation

  • While missing teeth and poor dental health were previously believed to be associated with an increased risk of pancreatic cancer, no one was certain what was causing the association. Dr. Ahn’s research supported by the Pancreatic Cancer Action Network found that two specific species of bacteria in the mouth are associated with a more than 50 percent increased risk of pancreatic cancer. These two bacteria could potentially serve as biomarkers, or important biological clues, that could help detect pancreatic cancer sooner in patients. Likewise, this opens up the possibility of studying whether efforts to reduce oral bacteria could decrease an individual’s risk of pancreatic cancer. Ahn’s important findings were recently published in a major publication, Gut, and were featured at the 2016 and 2017 American Association for Cancer Research Annual Meetings. She leveraged our $200,000 grant to gather the data necessary to secure a prestigious $2.8 million federal grant from the NCI.

    Read More

  • Improving Treatments
  • “One-two punch” combination therapy

  • David Boothman, PhD
    2012, 2014, 2015 grants
    Rising Tide Foundation
    George & June Block Family Foundation

  • We supported the development of a “one-two punch” combination therapy to knock out cancer. This dual-action therapy first tricks pancreatic cancer cells into poisoning themselves and then stops the cells from repairing the poison’s damage. The novel combination treatment will enter clinical trials in 2017. This represents the “translational” research that our grants help to accelerate, moving vital work from the lab to the clinic to reach patients.

    Read More

  • Unlocking the Biology
  • “Stop the Start” -- Understanding which cells lead to pancreatic cancer

  • Jennifer Bailey, PhD
    2011 Pathway to Leadership

  • Dr. Bailey’s project, called “Stop the Start,” focuses on pinpointing the very earliest events that cause normal pancreas cells to become cancerous and identifying the genetic alterations responsible. Importantly, her work successfully challenged and uprooted a long-held dogma in the field that pancreatic “ductal” adenocarcinoma only came from ductal cells. We now know that this is not true thanks to Bailey’s groundbreaking research which has been detailed in a number of leading publications. Understanding the biology of the normal cells within the pancreas helps identify which genetic changes take place to allow transformation into cancer cells — and each of those changes represents a potential drug target or a marker that could improve early detection. Bailey received this grant as a postdoctoral fellow at Johns Hopkins University, and she is now an independent investigator at University of Texas Health Science Center.

    Read More

  • Improving Treatments
  • Secret passage through stroma

  • Kazuki Sugahara, MD, PhD
    2012 Career Development Award
    and 2015 Translational
    The Daniel and Janet Mordecai Foundation

  • The complex and dense “stroma” surrounding pancreatic cancer cells has been a major barrier to delivering drugs to kill pancreatic cancer cells. Funded by two grants from the Pancreatic Cancer Action Network, Dr. Sugahara is developing a novel peptide that acts as a unique key to unlock a previously unknown secret door through the stroma to allow treatments to reach and kill cancer cells directly. His goal for his 2015 Translational Grant (with Andy Lowy co-PI) is to submit an Investigational New Drug application to the FDA in order to begin testing his treatment strategy in humans.

    Read More

  • Early Detection
  • Cyst juice to predict cancer risk

  • Michael Goggins, MD
    2013 Research Acceleration Network
    In Memory of Skip Viragh

  • Finding out that you have a cyst on your pancreas is a terrifying moment of uncertainty. What are the chances of the cyst becoming cancer? How soon should I take action and start treatment? To date, doctors have been unable to answer these questions with much certainty.

    Dr. Goggins and his research team are looking at the “juice” (fluid) from pancreatic cysts and determining the genetic features that predict the likelihood of progressing to cancer or remaining benign. Using this information in their high-risk screening program that is active at sites throughout the country, this research will improve outcomes for patients with pancreatic cancer while also sparing those with benign cysts from invasive procedures and toxic treatments.

    Read More

  • Improving Treatments
  • Studying how a new immunotherapy works in each patient

  • David Linehan, MD and
    Brian Wolpin, MD, MPH
    2016 Research Acceleration Network-2
    The Henry and Marilyn Taub Foundation

  • Thanks to the generosity of donors, we awarded our largest-ever grant of $2 million in 2016 to accelerate a large-scale clinical trial bringing a new immunotherapy to patients with pancreatic cancer. This novel treatment approach aims to block pancreatic cancer cells’ ability to hide from the patient’s immune system, so that the immune system can do its job of attacking and killing the cancer.

    A continuation of promising research from Dr. Linehan’s 2015 Translational Research Grant, also funded by the Pancreatic Cancer Action Network, this major clinical trial is a multi-institutional collaboration between two researchers, Drs. Linehan (at University of Rochester) and Wolpin (at Dana-Farber Cancer Institute), who both bring unique expertise to the project. Dr. Linehan’s team is conducting the large-scale clinical trial, while Dr. Wolpin’s team is simultaneously collecting and analyzing blood, bone marrow and tissue biopsies from patients at various stages of the disease and treatment — allowing the investigators to gain important knowledge from each and every patient treated with their regimen. Ideally, knowledge gained will help improve the treatment’s effectiveness and help identify which patients are most likely to respond positively, so that this targeted treatment can reach the patients who would benefit the most.

    Read More

Wage Hope With Us

Join us to double pancreatic cancer survival by 2020.

shop purple logo

Gear, apparel, accessories and more to show off your purple pride.

Shop Now 

©2019 Pancreatic Cancer Action Network. All rights reserved. Terms of Use | Privacy Policy

Pancreatic Cancer Action Network®, PanCAN®, PurpleStride®, Wage Hope®, Know Your Tumor®, Powerful Knowledge. Personal Treatment.®, Precision Promise℠ and Demand Better For Patients. For Survival.℠ are the trademarks of the Pancreatic Cancer Action Network, Inc.

The Pancreatic Cancer Action Network is registered as a 501©3 nonprofit organization. Contributions to the Pancreatic Cancer Action Network are tax-deductible to the extent permitted by law. The Pancreatic Cancer Action Network’s tax identification number is #33-0841281.